Business News

Takeda and MD Anderson Collaborate to Accelerate Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform

HOUSTON & OSAKA, Japan–(BUSINESS WIRE)–The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement and research agreement to develop cord blood-derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies, ‘armored’ with IL-15, for the treatment of B-cell malignancies and other …

Read More »

Allogene and Notch Therapeutics Partner for Development of iPSC-Derived Allogeneic Therapies for Hematologic Cancer Indications

SOUTH SAN FRANCISCO, Calif. and TORONTO, Nov. 05, 2019 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and Notch Therapeutics Inc., an immune cell therapy company creating universally compatible, allogeneic T cell therapies for …

Read More »

Siemens Healthineers Partners with Quanterix for Access to Nf-L Antibodies for Development of Nf-L Assays

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a licensing and supply arrangement with Siemens Healthineers for access to Quanterix’ proprietary Nf-L antibodies, which were recently acquired from UmanDiagnostics. Access to the Nf-L antibodies will …

Read More »

Stryker Announces Deal to Acquire Wright Medical for $4 Billion

Kalamazoo, Michigan, Nov. 04, 2019 (GLOBE NEWSWIRE) — Stryker (NYSE: SYK) announced today a definitive agreement to acquire all of the issued and outstanding ordinary shares of Wright Medical Group N.V. (NASDAQ: WMGI) for $30.75 per share, or a total equity value of approximately $4.0 billion and a total enterprise …

Read More »

Novartis Pays $80 Million for Pliant Therapeutics’ Preclinical NASH Candidate

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2019 /PRNewswire/ — Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced it has entered into a strategic collaboration and license agreement with Novartis covering the development and commercialization of Pliant’s …

Read More »

Philips and the US Department of Defense Develop Technology Using AI to Identify Infection Before Observable Symptoms

ANDOVER, Mass. & WASHINGTON–(BUSINESS WIRE)–Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, the Defense Threat Reduction Agency (DTRA), and Defense Innovation Unit (DIU) of the U.S. Department of Defense (DoD) today announced highlights from an 18-month project in predictive health monitoring aimed at developing an early warning …

Read More »

Takeda In-Licenses Investigational Celiac Disease Therapy from COUR Pharmaceuticals

OSAKA, Japan & CHICAGO–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and COUR Pharmaceutical Development Company, Inc. (“COUR”) today announced that Takeda has acquired an exclusive global license to develop and commercialize the investigational medicine CNP-101/TAK-101, an immune modifying nanoparticle containing gliadin proteins. Based on COUR’s antigen specific immune tolerance platform, …

Read More »

CRISPR Therapeutics Takes Over Joint Venture Casebia Therapeutics from Bayer

LEVERKUSEN, Germany and ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 21, 2019 /PRNewswire/ — CRISPR Therapeutics and Bayer today announced proposed plans whereby Casebia Therapeutics, a joint venture between CRISPR Therapeutics and Bayer, would operate under the direct management of CRISPR Therapeutics. Upon closing of the transaction, Casebia Therapeutics would focus …

Read More »

Alkermes Collaborates with Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230

DUBLIN, Oct. 21, 2019 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center (Fred Hutch) for ALKS 4230, Alkermes’ immuno-oncology drug candidate. ALKS 4230 is a novel, engineered fusion protein designed to selectively expand tumor-killing immune …

Read More »

Sartorius Signs Agreement to Acquire Select Danaher Life Science Platform Businesses for $750 Million in Cash

GÖTTINGEN, Germany–(BUSINESS WIRE)–Sartorius, a leading partner to the biopharmaceutical industry and laboratories, has signed an agreement to acquire parts of Danaher’s Life Science portfolio for approximately $750 million in cash. The businesses had combined sales turnover of approximately $140 million in 2018 with a strong growth profile and double-digit profit …

Read More »